Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Scientific Reports 12 (2022), 11846, 1-9
- Ereignis
-
Veröffentlichung
- (wo)
-
Münster
- (wer)
-
Universitäts- und Landesbibliothek Münster
- (wann)
-
2023
- Urheber
-
Schlack, Katrin
Seitzer, Konstantin Egon
Wüstmann, Neele
Humberg, Verena
Grundmann, Norbert
Steinestel, Julie
Tiedje, Dorothee
Rahbar, Kambiz
Krabbe, Laura-Maria
Bögemann, Martin
Schrader, Andres Jan
Bernemann, Christof
- DOI
-
10.17879/88988470916
- URN
-
urn:nbn:de:hbz:6-58988676858
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:43 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schlack, Katrin
- Seitzer, Konstantin Egon
- Wüstmann, Neele
- Humberg, Verena
- Grundmann, Norbert
- Steinestel, Julie
- Tiedje, Dorothee
- Rahbar, Kambiz
- Krabbe, Laura-Maria
- Bögemann, Martin
- Schrader, Andres Jan
- Bernemann, Christof
- Universitäts- und Landesbibliothek Münster
Entstanden
- 2023
Ähnliche Objekte (12)
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
EMT-specific circulating micro RNAs and circulating tumor cells in metastatic breast cancer
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Treatment with a 177Lutetium-radiolabeled ligand targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer: toxicity, efficacy and survival.
Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
EMT-specific circulating micro RNAs and circulating tumor cells in metastatic breast cancer
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Treatment with a 177Lutetium-radiolabeled ligand targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer: toxicity, efficacy and survival.
Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
EMT-specific circulating micro RNAs and circulating tumor cells in metastatic breast cancer
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Treatment with a 177Lutetium-radiolabeled ligand targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer: toxicity, efficacy and survival.